U.S. Markets close in 31 mins
  • S&P 500

    3,580.17
    +22.63 (+0.64%)
     
  • Dow 30

    29,609.01
    +345.53 (+1.18%)
     
  • Nasdaq

    11,897.70
    +42.73 (+0.36%)
     
  • Russell 2000

    1,785.34
    +1.21 (+0.07%)
     
  • Crude Oil

    42.17
    +0.43 (+1.03%)
     
  • Gold

    1,869.60
    +8.10 (+0.44%)
     
  • Silver

    24.23
    +0.18 (+0.74%)
     
  • EUR/USD

    1.1862
    -0.0014 (-0.1186%)
     
  • 10-Yr Bond

    0.8570
    +0.0280 (+3.38%)
     
  • Vix

    23.70
    +0.59 (+2.55%)
     
  • GBP/USD

    1.3291
    +0.0038 (+0.2858%)
     
  • USD/JPY

    103.8280
    +0.0570 (+0.0549%)
     
  • BTC-USD

    18,385.21
    -69.54 (-0.38%)
     
  • CMC Crypto 200

    363.64
    +2.21 (+0.61%)
     
  • FTSE 100

    6,351.45
    +17.10 (+0.27%)
     
  • Nikkei 225

    25,527.37
    -106.93 (-0.42%)
     

Syneos Health to Present at Upcoming Investor Conferences

Syneos Health, Inc.
·1 min read

MORRISVILLE, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that management is scheduled to present at two upcoming investor conferences:

  • Credit Suisse Virtual Healthcare Conference: Chief Financial Officer Jason Meggs is scheduled to present on Monday, November 9, 2020, at 9:30 a.m. EST.

  • Jefferies Virtual London Healthcare Conference: Chief Executive Officer Alistair Macdonald and Chief Financial Officer Jason Meggs are scheduled to present on Thursday, November 19, 2020, at 11:25 a.m. EST/4:25 p.m. GMT.

A live webcast of each event, along with presentation materials and archived audio replays of each presentation will be available on the Company’s Investor Relations website at investor.syneoshealth.com.

About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

Contacts

Investor Relations:

Press/Media:

Ronnie Speight

Danielle DeForge

Senior Vice President, Investor Relations

Vice President, External Communications

+1 919 745 2745

+1 202 210 5992

Investor.Relations@syneoshealth.com

danielle.deforge@syneoshealth.com